Revalesio has announced that two abstracts featuring its investigational treatment RNS60 in acute ischaemic stroke have been accepted for oral presentation at the Society of NeuroInterventional Surgery (SNIS) annual meeting (14–18 July, Nashville, USA).
The presentations will highlight the objectives and design of the company’s upcoming Phase 3 clinical trial in acute ischaemic stroke, RESTORE, as well as a new post-hoc analysis from its prior Phase 2 RESCUE study of RNS60. Both presentations are scheduled for Thursday 17 July.
The two presentations are as follows:
- ‘RESTORE: a Phase 3 study evaluating efficacy and safety of RNS60 as an adjunct cytoprotective treatment in patients with acute ischaemic stroke undergoing endovascular thrombectomy’
- ‘Post-hoc analysis of RESCUE shows improvement in all prespecified efficacy endpoints in participants enrolled <12 hours since symptom onset’
RNS60 is a novel, investigational therapy being evaluated as an adjunct treatment for patients with acute ischaemic stroke undergoing endovascular thrombectomy. The therapy targets infarct growth reduction during the acute injury phase, thereby aiming to increase the number of stroke survivors who retain their functional independence, according to Revalesio.
“What is unique about the design of our Phase 2 RESCUE trial is that we focused on demonstrating RNS60’s ability to decrease the growth of the infarct or brain tissue loss after a stroke, post-endovascular thrombectomy,” said Greg Archambeau, president of Revalesio and co-inventor of RNS60. “As we have presented at past conferences, patients treated with high-dose RNS60 in the RESCUE trial had less brain volume loss compared to placebo—and, as one would expect, less brain tissue loss correlated with better patient outcomes.”
